RUBICON RESEARCH LIMITED
₹ 461 - ₹ 485
09-Oct-2025 - 13-Oct-2025
₹ 14550.00

/ 30 Shares

RUBICON RESEARCH LIMITED

09-Oct-2025 - 13-Oct-2025

₹ 461 - ₹ 485

Price Band

₹ 14550.00

Minimum Investment

30

Bid Lot

28,553,497

Shares

IPO Details

Category % Shares/Amount
QIB 75% 21,274,470 Shares RS.1031.81 CR
HNI 1 5% 1,418,297 Shares RS.68.79 CR @ 3377 FORM 1X
HNI 2 10% 2,836,596 Shares RS.137.57 CR @ 6754 FORM 1X
Retail 10% 2,836,595 Shares RS.137.57 CR @ 94553 FORM 1X
Employee 0% 39,863 Shares RS.1.75 CR

Application Require for 1 Time

Retail (Upto 2 Lakh) HNI (2 Lakh to 10 Lakh) HNI (Above 10 Lakh)
94553 FORM 1X 3377 FORM 1X 6754 FORM 1X

IPO Lot Size

Category Lots Shares Amount
Retail (Upto 2 Lakh) 1 30 ₹ 14,550
Retail (Upto 2 Lakh) 13 390 ₹ 189,150
S-HNI (2 Lakh to 10 Lakh) 14 420 ₹ 203,700
S-HNI (2 Lakh to 10 Lakh) 68 2040 ₹ 989,400
B-HNI (Above 10 Lakh) 69 2070 ₹ 1,003,950

IPO Timeline

  • Open Date

    09-Oct-2025

  • Close Date

    13-Oct-2025

  • Basis of Allotment Date

    14-Oct-2025

  • Initiation of Refunds

    15-Oct-2025

  • Credit Shares to Demat A/c

    15-Oct-2025

  • IPO Listing Date

    16-Oct-2025

Subscription as on
10-Oct-2025 17:57

Category Book Size Subscription No. of Times
QIB 8,509,788 ₹ 412.72 Cr. 18,917,340 ₹ 917.49 Cr. 2.22x
HNI (<10 LAKH) 1,418,297 ₹ 68.79 Cr. 3,652,350 ₹ 177.14 Cr. 2.58x
HNI2 (>10 LAKH) 2,836,596 ₹ 137.57 Cr. 4,540,560 ₹ 220.22 Cr. 1.60x
RETAIL 2,984,271 ₹ 144.74 Cr. 11,898,690 ₹ 577.09 Cr. 3.99x
EMP 39,863 ₹ 1.93 Cr. 94,590 ₹ 4.59 Cr. 2.37x
Total 15,788,815 39,103,530 2.48x
Category Book Size Subscription No. of Times
QIB 8,509,788 ₹ 412.72 Cr. 18,917,340 ₹ 917.49 Cr. 2.22x
HNI (<10 LAKH) 1,418,297 ₹ 68.79 Cr. 3,652,350 ₹ 177.14 Cr. 2.58x
HNI2 (>10 LAKH) 2,836,596 ₹ 137.57 Cr. 4,540,560 ₹ 220.22 Cr. 1.60x
RETAIL 2,984,271 ₹ 144.74 Cr. 11,898,690 ₹ 577.09 Cr. 3.99x
EMP 39,863 ₹ 1.93 Cr. 94,590 ₹ 4.59 Cr. 2.37x
Total 15,788,815 39,103,530 2.48x

*Excluding Anchor

Total No. of Application Approx : ~318109 (3.20 Appwise)

Appwise Subscription
Category Total App App wise
HNIBT 8002.99 3377 (For 1x) 2.37x
HNIAT 2116.50 6754 (For 1x) 0.31x
RETAIL 315508.00 94553 (For 1x) 3.34x

Disclaimer: The above-mentioned information / data are sourced from the websites of National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) and are subject to change on real time basis. For updated information / data you can visit their respective website. The information / data provided herein above are for information purpose only and provided "AS IS" and "AS AVAILABLE" basis and without warranty, express or implied. We do not guarantee or warrant the accuracy, adequacy or completeness of the information received through the said websites. “We” hold not responsibility of any kind as regard to any discrepancies, errors, omissions, losses or damages. “We” including its affiliates and any of its officers, directors, personnel and employees, shall not liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of information / data received through the said websites. The recipient alone shall be fully responsible / are liable for any decision taken on the basis of such information / data. All recipients should before acting upon the said information make their own investigation, seek appropriate professional advice.

About Company

Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, and commercialization of differentiated formulations.

As of June 30, 2025, Rubicon Research had a portfolio of 72 active Abbreviated New Drug Application (ANDA) and New Drug Application (NDA) products approved by the US FDA. The company’s portfolio includes 66 commercialized products, with a US generic pharmaceutical market size of USD 2,455.7 million, of which Rubicon Research Limited contributed USD 195 million in Fiscal 2024.

As of June 30, 2025, the company has 17 new products awaiting US FDA ANDA approval and 63 products at various stages of development.

As of June 30, 2025, the company marketed over 350 SKUs to 96 customers, including three major wholesalers who, account for more than 90% of wholesale drug distribution in the US. The company also supplies group purchasing organizations (GPOs), national pharmacy chains, regional pharmacy chains, and managed care organizations.

Beyond the US market, Rubicon Research Limited, directly or through third-party distribution partners, has registered or filed 48 product applications across Australia, the United Kingdom, Singapore, Saudi Arabia, and the United Arab Emirates and expects to commence commercial activities upon approval. The company also provides contract manufacturing services to select customers in India, Australia, and New Zealand.

Rubicon Research Limited operates three manufacturing facilities in India and two US FDA inspected R&D facilities-one each in India and Canada.

Read More

Strengths

  • Fastest-growing Indian pharmaceutical company amongst peers.
  • Data-driven product selection framework
  • Strong R&D capabilities
  • Robust sales and distribution capabilities in the US
  • Strong track record of compliance combined with expertise in cost effective manufacturing
  • Experienced and entrepreneurial management team

Company Promoters

Company Financials

Period Ended 30 Jun 2025 31 Mar 2025 31 Mar 2024 31 Mar 2023
Assets 1,647.60 1,451.43 1,109.49 749.70
Total Income 356.95 1,296.22 872.39 419.00
Profit After Tax 43.30 134.36 91.01 -16.89
EBITDA 79.74 267.89 173.09 43.97
NET Worth 593.67 540.98 385.00 286.38
Reserves and Surplus 397.50 525.57 369.79 281.31
Total Borrowing 495.78 393.17 396.41 317.91
Amount in ? Crore

Objects of the Issue

The Company Rubicon Research IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:

S.No. Objects of the Issue Expected Amount (in Millions)
1 Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by the Company 3,100
2 Funding inorganic growth through unidentified acquisitions and other strategic initiatives and General corporate purposes

How to Apply

Apply for IPO in few simple steps.

  • Step 01 :

    Once you create your account, Login to InvestoYard.

  • Step 02 :

    Under IPO Section, you will be able to see a list of Ongoing IPOs, where you can click on apply button.

  • Step 03 :

    Add quantity of shares to apply – Maximum 3 bids are allowed (For retail category – max amount Rs.2,00,000/-).

  • Step 04 :

    Enter your UPI ID and you will receive mandate on your UPI App.

  • Step 05 :

    Once you accept the mandate, Application is submitted successful.

  • Applying for an IPO is easier than ever with InvestoYard, in just a few clicks your application is processed. You can bid for any IPO through InvestoYard, the bidding process is simple and hassle free. Every company has a lot size decided & you can buy in multiples of the decided lot.
  • If lot size is 15, then you have to bid for multiples of 15 share like 30,45,60 and so on.
  • The maximum subscription amount for retail investors is 2 lakh.
  • Any bid can be at a desired price or cut off price given by the company.

  • Enter the number of shares you wish to buy, as per the lot size.
  • You can apply at the cut off price set by the company or bid for a desired amount within the price band.
  • Maximum three bids will be accepted.
  • You then need to enter the UPI ID on InvestoYard’s IPO application form.

  • You will immediately get a fund blocked request on your UPI for the submitted IPO application.
  • The funds will be blocked in your bank account until allotment when it is debited.
  • The limit for IPO application is Rs 2 lakh per transaction on UPI.
  • On allotment of the shares, the money will be automatically debited.
  • If the share aren’t allotted the blocked funds will reflect back into your account.

Frequently Asked Questions

Apply Now